mRNA Vaccines and RNAi Therapeutics Market By Disease Type (Hereditary transthyretin-mediated amyloidosis genetic, Acute hepatic porphyria, Primary hyperoxaluria type 1, Atherosclerotic cardiovascular disease), By Route of administration (IV infusion, Subcutaneous), By End user (Research Institutes, Hospitals and clinics): Global Opportunity Analysis and Industry Forecast, 2021-2031
The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.
The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects. In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.
The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include the Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, and TIBA Biotech.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
Hereditary transthyretin-mediated amyloidosis genetic
Acute hepatic porphyria
Primary hyperoxaluria type 1
Atherosclerotic cardiovascular disease
By Route of administration
IV infusion
Subcutaneous
By End user
Research Institutes
Hospitals and clinics
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Alnylam Pharmaceuticals
BioNTech AG
Curevac AG
Etherna Immunotherapies
Ethris GMBH
IN-CELL-ART
Moderna Therapeutics
Sangamo Therapeutics, Inc.
Sanofi AG
SCM Life Sciences (Argos Therapeutics, Inc. )
Sarepta Therapeutics
Arcturus Therapeutics
Ionis Pharmaceuticals, Inc
Nutcracker
Tiba Biotech
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Hereditary transthyretin-mediated amyloidosis genetic
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Acute hepatic porphyria
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Primary hyperoxaluria type 1
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Atherosclerotic cardiovascular disease
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 IV infusion
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Subcutaneous
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Research Institutes
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Hospitals and clinics
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Type
- 7.2.3 North America Market size and forecast, by Route of administration
- 7.2.4 North America Market size and forecast, by End user
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Disease Type
- 7.2.5.1.2 Market size and forecast, by Route of administration
- 7.2.5.1.3 Market size and forecast, by End user
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Disease Type
- 7.2.5.2.2 Market size and forecast, by Route of administration
- 7.2.5.2.3 Market size and forecast, by End user
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Disease Type
- 7.2.5.3.2 Market size and forecast, by Route of administration
- 7.2.5.3.3 Market size and forecast, by End user
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Type
- 7.3.3 Europe Market size and forecast, by Route of administration
- 7.3.4 Europe Market size and forecast, by End user
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Disease Type
- 7.3.5.1.2 Market size and forecast, by Route of administration
- 7.3.5.1.3 Market size and forecast, by End user
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Disease Type
- 7.3.5.2.2 Market size and forecast, by Route of administration
- 7.3.5.2.3 Market size and forecast, by End user
- 7.3.5.3 U.K.
- 7.3.5.3.1 Market size and forecast, by Disease Type
- 7.3.5.3.2 Market size and forecast, by Route of administration
- 7.3.5.3.3 Market size and forecast, by End user
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Disease Type
- 7.3.5.4.2 Market size and forecast, by Route of administration
- 7.3.5.4.3 Market size and forecast, by End user
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Disease Type
- 7.3.5.5.2 Market size and forecast, by Route of administration
- 7.3.5.5.3 Market size and forecast, by End user
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Disease Type
- 7.3.5.6.2 Market size and forecast, by Route of administration
- 7.3.5.6.3 Market size and forecast, by End user
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3 Asia-Pacific Market size and forecast, by Route of administration
- 7.4.4 Asia-Pacific Market size and forecast, by End user
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Disease Type
- 7.4.5.1.2 Market size and forecast, by Route of administration
- 7.4.5.1.3 Market size and forecast, by End user
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Disease Type
- 7.4.5.2.2 Market size and forecast, by Route of administration
- 7.4.5.2.3 Market size and forecast, by End user
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Disease Type
- 7.4.5.3.2 Market size and forecast, by Route of administration
- 7.4.5.3.3 Market size and forecast, by End user
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Disease Type
- 7.4.5.4.2 Market size and forecast, by Route of administration
- 7.4.5.4.3 Market size and forecast, by End user
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Disease Type
- 7.4.5.5.2 Market size and forecast, by Route of administration
- 7.4.5.5.3 Market size and forecast, by End user
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Disease Type
- 7.4.5.6.2 Market size and forecast, by Route of administration
- 7.4.5.6.3 Market size and forecast, by End user
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Type
- 7.5.3 LAMEA Market size and forecast, by Route of administration
- 7.5.4 LAMEA Market size and forecast, by End user
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Disease Type
- 7.5.5.1.2 Market size and forecast, by Route of administration
- 7.5.5.1.3 Market size and forecast, by End user
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Disease Type
- 7.5.5.2.2 Market size and forecast, by Route of administration
- 7.5.5.2.3 Market size and forecast, by End user
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Disease Type
- 7.5.5.3.2 Market size and forecast, by Route of administration
- 7.5.5.3.3 Market size and forecast, by End user
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Disease Type
- 7.5.5.4.2 Market size and forecast, by Route of administration
- 7.5.5.4.3 Market size and forecast, by End user
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Alnylam Pharmaceuticals
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 BioNTech AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Curevac AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Etherna Immunotherapies
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Ethris GMBH
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 IN-CELL-ART
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Moderna Therapeutics
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Sangamo Therapeutics, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Sanofi AG
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 SCM Life Sciences (Argos Therapeutics, Inc. )
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Sarepta Therapeutics
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Arcturus Therapeutics
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Ionis Pharmaceuticals, Inc
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Nutcracker
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Tiba Biotech
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 2. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR ACUTE HEPATIC PORPHYRIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR ACUTE HEPATIC PORPHYRIA BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR PRIMARY HYPEROXALURIA TYPE 1, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR PRIMARY HYPEROXALURIA TYPE 1 BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. GLOBAL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 11. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR IV INFUSION, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR IV INFUSION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR SUBCUTANEOUS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR SUBCUTANEOUS BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. GLOBAL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 16. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR RESEARCH INSTITUTES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. MRNA VACCINES AND RNAI THERAPEUTICS MARKET SIZE, FOR HOSPITALS AND CLINICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. MRNA VACCINES AND RNAI THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 22. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 23. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 24. NORTH AMERICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 26. U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 27. U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 28. CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 29. CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 30. CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 31. MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 32. MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 33. MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 34. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 35. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 36. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 37. EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 38. GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 39. GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 40. GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 41. FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 42. FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 43. FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 44. U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 45. U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 46. U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 47. ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 48. ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 49. ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 50. SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 51. SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 52. SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 53. REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 54. REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 55. REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 56. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 57. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 58. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 59. ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 60. CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 61. CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 62. CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 63. JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 64. JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 65. JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 66. INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 67. INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 68. INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 69. AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 70. AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 71. AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 72. SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 73. SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 74. SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 75. REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 76. REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 77. REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 78. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 79. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 80. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 81. LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 82. BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 83. BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 84. BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 85. SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 86. SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 87. SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 88. SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 89. SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 90. SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 91. REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
- TABLE 92. REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 93. REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 94.ALNYLAM PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 95.ALNYLAM PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 96.ALNYLAM PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 97.ALNYLAM PHARMACEUTICALS: NET SALES,
- TABLE 98.ALNYLAM PHARMACEUTICALS: KEY STRATERGIES
- TABLE 99.BIONTECH AG: COMPANY SNAPSHOT
- TABLE 100.BIONTECH AG: OPERATING SEGMENTS
- TABLE 101.BIONTECH AG: PRODUCT PORTFOLIO
- TABLE 102.BIONTECH AG: NET SALES,
- TABLE 103.BIONTECH AG: KEY STRATERGIES
- TABLE 104.CUREVAC AG: COMPANY SNAPSHOT
- TABLE 105.CUREVAC AG: OPERATING SEGMENTS
- TABLE 106.CUREVAC AG: PRODUCT PORTFOLIO
- TABLE 107.CUREVAC AG: NET SALES,
- TABLE 108.CUREVAC AG: KEY STRATERGIES
- TABLE 109.ETHERNA IMMUNOTHERAPIES: COMPANY SNAPSHOT
- TABLE 110.ETHERNA IMMUNOTHERAPIES: OPERATING SEGMENTS
- TABLE 111.ETHERNA IMMUNOTHERAPIES: PRODUCT PORTFOLIO
- TABLE 112.ETHERNA IMMUNOTHERAPIES: NET SALES,
- TABLE 113.ETHERNA IMMUNOTHERAPIES: KEY STRATERGIES
- TABLE 114.ETHRIS GMBH: COMPANY SNAPSHOT
- TABLE 115.ETHRIS GMBH: OPERATING SEGMENTS
- TABLE 116.ETHRIS GMBH: PRODUCT PORTFOLIO
- TABLE 117.ETHRIS GMBH: NET SALES,
- TABLE 118.ETHRIS GMBH: KEY STRATERGIES
- TABLE 119.IN-CELL-ART: COMPANY SNAPSHOT
- TABLE 120.IN-CELL-ART: OPERATING SEGMENTS
- TABLE 121.IN-CELL-ART: PRODUCT PORTFOLIO
- TABLE 122.IN-CELL-ART: NET SALES,
- TABLE 123.IN-CELL-ART: KEY STRATERGIES
- TABLE 124.MODERNA THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 125.MODERNA THERAPEUTICS: OPERATING SEGMENTS
- TABLE 126.MODERNA THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 127.MODERNA THERAPEUTICS: NET SALES,
- TABLE 128.MODERNA THERAPEUTICS: KEY STRATERGIES
- TABLE 129.SANGAMO THERAPEUTICS, INC.: COMPANY SNAPSHOT
- TABLE 130.SANGAMO THERAPEUTICS, INC.: OPERATING SEGMENTS
- TABLE 131.SANGAMO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
- TABLE 132.SANGAMO THERAPEUTICS, INC.: NET SALES,
- TABLE 133.SANGAMO THERAPEUTICS, INC.: KEY STRATERGIES
- TABLE 134.SANOFI AG: COMPANY SNAPSHOT
- TABLE 135.SANOFI AG: OPERATING SEGMENTS
- TABLE 136.SANOFI AG: PRODUCT PORTFOLIO
- TABLE 137.SANOFI AG: NET SALES,
- TABLE 138.SANOFI AG: KEY STRATERGIES
- TABLE 139.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): COMPANY SNAPSHOT
- TABLE 140.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): OPERATING SEGMENTS
- TABLE 141.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): PRODUCT PORTFOLIO
- TABLE 142.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): NET SALES,
- TABLE 143.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ): KEY STRATERGIES
- TABLE 144.SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 145.SAREPTA THERAPEUTICS: OPERATING SEGMENTS
- TABLE 146.SAREPTA THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 147.SAREPTA THERAPEUTICS: NET SALES,
- TABLE 148.SAREPTA THERAPEUTICS: KEY STRATERGIES
- TABLE 149.ARCTURUS THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 150.ARCTURUS THERAPEUTICS: OPERATING SEGMENTS
- TABLE 151.ARCTURUS THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 152.ARCTURUS THERAPEUTICS: NET SALES,
- TABLE 153.ARCTURUS THERAPEUTICS: KEY STRATERGIES
- TABLE 154.IONIS PHARMACEUTICALS, INC: COMPANY SNAPSHOT
- TABLE 155.IONIS PHARMACEUTICALS, INC: OPERATING SEGMENTS
- TABLE 156.IONIS PHARMACEUTICALS, INC: PRODUCT PORTFOLIO
- TABLE 157.IONIS PHARMACEUTICALS, INC: NET SALES,
- TABLE 158.IONIS PHARMACEUTICALS, INC: KEY STRATERGIES
- TABLE 159.NUTCRACKER: COMPANY SNAPSHOT
- TABLE 160.NUTCRACKER: OPERATING SEGMENTS
- TABLE 161.NUTCRACKER: PRODUCT PORTFOLIO
- TABLE 162.NUTCRACKER: NET SALES,
- TABLE 163.NUTCRACKER: KEY STRATERGIES
- TABLE 164.TIBA BIOTECH: COMPANY SNAPSHOT
- TABLE 165.TIBA BIOTECH: OPERATING SEGMENTS
- TABLE 166.TIBA BIOTECH: PRODUCT PORTFOLIO
- TABLE 167.TIBA BIOTECH: NET SALES,
- TABLE 168.TIBA BIOTECH: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.MRNA VACCINES AND RNAI THERAPEUTICS MARKET SEGMENTATION
- FIGURE 2.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031
- FIGURE 3.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.MRNA VACCINES AND RNAI THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,BY DISEASE TYPE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ACUTE HEPATIC PORPHYRIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PRIMARY HYPEROXALURIA TYPE 1 MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 17.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF IV INFUSION MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUBCUTANEOUS MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 20.MRNA VACCINES AND RNAI THERAPEUTICS MARKET,BY END USER,2021(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RESEARCH INSTITUTES MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031(%)
- FIGURE 23.MRNA VACCINES AND RNAI THERAPEUTICS MARKET BY REGION,2021
- FIGURE 24.U.S. MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 25.CANADA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 26.MEXICO MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 27.GERMANY MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 28.FRANCE MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 29.U.K. MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 30.ITALY MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 31.SPAIN MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 32.REST OF EUROPE MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 33.CHINA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 34.JAPAN MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 35.INDIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 36.AUSTRALIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 37.SOUTH KOREA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 38.REST OF ASIA-PACIFIC MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 39.BRAZIL MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 40.SAUDI ARABIA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 41.SOUTH AFRICA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 42.REST OF LAMEA MRNA VACCINES AND RNAI THERAPEUTICS MARKET,2021-2031($MILLION)
- FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 47.COMPETITIVE DASHBOARD
- FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 49.ALNYLAM PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 50.BIONTECH AG.: NET SALES ,($MILLION)
- FIGURE 51.CUREVAC AG.: NET SALES ,($MILLION)
- FIGURE 52.ETHERNA IMMUNOTHERAPIES.: NET SALES ,($MILLION)
- FIGURE 53.ETHRIS GMBH.: NET SALES ,($MILLION)
- FIGURE 54.IN-CELL-ART.: NET SALES ,($MILLION)
- FIGURE 55.MODERNA THERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 56.SANGAMO THERAPEUTICS, INC..: NET SALES ,($MILLION)
- FIGURE 57.SANOFI AG.: NET SALES ,($MILLION)
- FIGURE 58.SCM LIFE SCIENCES (ARGOS THERAPEUTICS, INC. ).: NET SALES ,($MILLION)
- FIGURE 59.SAREPTA THERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 60.ARCTURUS THERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 61.IONIS PHARMACEUTICALS, INC.: NET SALES ,($MILLION)
- FIGURE 62.NUTCRACKER.: NET SALES ,($MILLION)
- FIGURE 63.TIBA BIOTECH.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook